Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant atezolizumab plus T-AC/EC versus T-AC/EC alone in triple-negative breast cancer
2016-003695-47Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Roche. Primary endpoint: iDFS. Started Jan 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2016-003695-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003695-47.